Altamira Therapeutics Statistics
Total Valuation
CYTO has a market cap or net worth of $3.54 million. The enterprise value is $3.00 million.
Market Cap | 3.54M |
Enterprise Value | 3.00M |
Important Dates
The last earnings date was Wednesday, April 10, 2024, before market open.
Earnings Date | Apr 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
CYTO has 2.24 million shares outstanding. The number of shares has increased by 1,066.00% in one year.
Shares Outstanding | 2.24M |
Shares Change (YoY) | +1,066.00% |
Shares Change (QoQ) | +13.79% |
Owned by Insiders (%) | 0.89% |
Owned by Institutions (%) | 0.34% |
Float | 2.22M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.50 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.02.
Current Ratio | 1.38 |
Quick Ratio | 0.78 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1.32 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -55.30% |
Return on Capital (ROIC) | -90.21% |
Revenue Per Employee | n/a |
Profits Per Employee | -$460,616 |
Employee Count | 10 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.12% in the last 52 weeks. The beta is 2.54, so CYTO's price volatility has been higher than the market average.
Beta (1Y) | 2.54 |
52-Week Price Change | -92.12% |
50-Day Moving Average | 1.85 |
200-Day Moving Average | 4.12 |
Relative Strength Index (RSI) | 43.29 |
Average Volume (30 Days) | 1,203,248 |
Short Selling Information
The latest short interest is 444,464, so 19.84% of the outstanding shares have been sold short.
Short Interest | 444,464 |
Short Previous Month | 61,731 |
Short % of Shares Out | 19.84% |
Short % of Float | 20.03% |
Short Ratio (days to cover) | 0.03 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -6.48M |
Pretax Income | -4.23M |
Net Income | -4.61M |
EBITDA | -2.28M |
EBIT | -2.41M |
Earnings Per Share (EPS) | -$8.63 |
Balance Sheet
The company has $675,784 in cash and $109,082 in debt, giving a net cash position of $566,702 or $0.25 per share.
Cash & Cash Equivalents | 675,784 |
Total Debt | 109,082 |
Net Cash | 566,702 |
Net Cash Per Share | $0.25 |
Equity / Book Value | 7.07M |
Book Value Per Share | 3.16 |
Working Capital | 365,842 |
Cash Flow
Operating Cash Flow | -12.60M |
Capital Expenditures | n/a |
Free Cash Flow | -12.60M |
FCF Per Share | -$31.68 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CYTO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,066.00% |
Shareholder Yield | -1,066.00% |
Earnings Yield | -129.31% |
FCF Yield | -353.72% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 13, 2023. It was a reverse split with a ratio of 1:20.
Last Split Date | Dec 13, 2023 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |